Nalmefene is a small molecule commercialized by Opiant Pharmaceuticals, with a leading Pre-Registration program in Acute Opioid Overdosage. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Nalmefene’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Nalmefene is expected to reach an annual total of $353 mn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Nalmefene Overview

Nalmefene (OPNT-003) is under development for the treatment of opioid overdose. It is a long acting nasal spray, administered through intranasal route using intravail and nasal drug delivery technology. The drug candidate acts by targeting opioid receptors (delta,kappa and mu types).

Opiant Pharmaceuticals Overview

Opiant Pharmaceuticals (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.

The company reported revenues of (US Dollars) US$47.8 million for the fiscal year ended December 2021 (FY2021), an increase of 61.3% over FY2020. The operating profit of the company was US$5.2 million in FY2021, compared to an operating loss of US$2.2 million in FY2020. The net profit of the company was US$3 million in FY2021, compared to a net loss of US$1.9 million in FY2020. The company reported revenues of US$0.2 million for the third quarter ended September 2022, a decrease of 95.5% over the previous quarter.

For a complete picture of Nalmefene’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.